Cancer

ORIC® Pharmaceuticals to Present Initial Data from Phase 1b Trial of ORIC-944 in Combination with Androgen Receptor Inhibitors in Patients with mCRPC

Conference Call and Webcast on Wednesday, May 28, 2025, at 4:30 p.m. ETSOUTH SAN FRANCISCO, Calif. and SAN DIEGO, May…

7 months ago

Psyence BioMed Finalizes Agreement with Award-Winning CRO Southern Star Research to Accelerate Phase IIb Clinical Trial

New York, New York--(Newsfile Corp. - May 27, 2025) - Psyence BioMed (NASDAQ: PBM) ("Psyence BioMed" or the "Company"), a…

7 months ago

Brain Cancer Canada Awards $85K to Cutting-Edge Recurrent Glioblastoma Research

TORONTO, May 26, 2025 (GLOBE NEWSWIRE) -- Brain Cancer Canada is pleased to announce a $85,000 research grant awarded to…

7 months ago

ZLNA – Issuance of shares through set-off of option exercise fee

Oslo, 24 May 2025: Zelluna ASA (the "Company") refers to the resolution by the Company's Annual General Meeting held on…

7 months ago

IMUNON Announces Up To $9.75 Million Private Placement Priced At-The-Market Under Nasdaq Rules

$3.25 million upfront with up to an additional $6.5 million of potential aggregate gross proceeds upon the exercise in full of…

7 months ago

INDY 500 Stars Join Forces with ZERO Prostate Cancer to Put Veterans’ Health in the Spotlight at Memorial Day Weekend Races

INDIANAPOLIS, May 23, 2025 /PRNewswire/ -- This Memorial Day Weekend, the spotlight won't only be on speed—it'll be on saving lives.…

7 months ago

RED DOOR COMMUNITY LAUNCHES NEW “COMMUNITY CONNECTIONS” BLOG AS A RESOURCE FOR THOSE IMPACTED BY CANCER

This new platform offers an opportunity to share expert insights, common experiences, and inspirations as we explore the realities of…

7 months ago

AI Could Add $461 Billion to Global Healthcare–And These New Platforms Are Leading the Charge

Equity Insider News Commentary Issued on behalf of Avant Technologies Inc. VANCOUVER, BC, May 23, 2025 /PRNewswire/ -- Equity Insider…

7 months ago

CHMP recommends EU approval of Roche’s Itovebi for PIK3CA-mutated, ER-positive, HER2-negative, advanced breast cancer

Positive recommendation based on phase III INAVO120 data showing ItovebiTM (inavolisib) in combination with palbociclib and fulvestrant more than doubled…

7 months ago

Syncromune® Inc. Announces Publication of Abstract on SYNC-T® Therapy SV-102 Phase 1 Data for Metastatic Prostate Cancer at ASCO 2025 Annual Meeting

Study Demonstrated 87% Overall Response Rate in Metastatic Prostate Cancer Patients Treated with SYNC-T, a First-in-Class In Situ Personalized Immunotherapy…

7 months ago